Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Part II: The Endocannabinoids and Regulation of Energy Balance; The Endocannabinoid System: a Target for Anti-Obesity Drugs

Contribution of CB1 blockade to the management of high-risk abdominal obesity

International Journal of Obesity volume 30, pages S44–S52 (2006)Cite this article

Abstract

The worldwide increase in the prevalence of type 2 diabetes represents a tremendous challenge for our healthcare system, especially if we consider that this phenomenon is largely explained by the epidemic of obesity. However, despite the well-recognized increased morbidity and mortality associated with an elevated body weight, there is now more and more evidence highlighting that abdominal adipose tissue is the fat depot that conveys the greatest risk of metabolic complications. This cluster of metabolic abnormalities has been referred to as the metabolic syndrome and this condition is largely the consequence of abdominal obesity, especially when accompanied by a high accumulation of visceral adipose tissue. This cluster of metabolic complications has also been found to be predictive of a substantially increased risk of coronary heart disease beyond the presence of traditional risk factors. Moreover, a moderate weight loss in initially abdominally obese patients is associated with a selective mobilization of visceral adipose tissue, leading to improvements in the metabolic risk profile predictive of a reduced risk of coronary heart disease and of type 2 diabetes. The recent discovery of the endocannabinoid-CB1 receptor system and of its impact on the regulation of energy metabolism represents a significant advance, which will help physicians target abdominal obesity and its related metabolic complications. In this regard, studies have shown that rimonabant therapy (the first developed CB1 blocker) could be useful for the management of clustering cardiovascular disease risk factors in high-risk abdominally obese patients through its effects not only on energy balance but also on adipose tissue metabolism. For instance, the presence of CB1 receptors in adipose tissue and the recently reported effect of rimonabant on adiponectin production by adipose cells may represent a key factor responsible for the weight loss-independent effect of this CB1 blocker on cardiometabolic risk variables.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Kissebah AH, Freedman DS, Peiris AN . Health risk of obesity. Med Clin North Am 1989; 73: 111–138.

    CAS  PubMed  Google Scholar 

  2. Bray GA . Complications of obesity. Ann Intern Med 1985; 103: 1052–1062.

    CAS  PubMed  Google Scholar 

  3. Pascot A, Lemieux I, Prud’homme D, Tremblay A, Nadeau A, Couillard C et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001; 42: 2007–2014.

    CAS  PubMed  Google Scholar 

  4. Pouliot MC, Després JP, Nadeau A, Moorjani S, Prud’homme D, Lupien PJ et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41: 826–834.

    CAS  PubMed  Google Scholar 

  5. Tchernof A, Lamarche B, Prud’homme D, Nadeau A, Moorjani S, Labrie F et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996; 19: 629–637.

    CAS  PubMed  Google Scholar 

  6. Lemieux I, Pascot A, Prud’homme D, Alméras N, Bogaty P, Nadeau A et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21: 961–967.

    CAS  PubMed  Google Scholar 

  7. Couillard C, Bergeron N, Prud’homme D, Bergeron J, Tremblay A, Bouchard C et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 1998; 47: 953–960.

    CAS  PubMed  Google Scholar 

  8. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C . Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497–511.

    PubMed  Google Scholar 

  9. Després JP, Moorjani S, Ferland M, Tremblay A, Lupien PJ, Nadeau A et al. Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Arteriosclerosis 1989; 9: 203–210.

    PubMed  Google Scholar 

  10. Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA . Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab 2003; 88: 2534–2540.

    CAS  PubMed  Google Scholar 

  11. Ross R, Freeman J, Hudson R, Janssen I . Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002; 87: 5044–5051.

    CAS  PubMed  Google Scholar 

  12. Van Gaal LF, Vansant GA, De Leeuw IH . Upper body adiposity and the risk for atherosclerosis. J Am Coll Nutr 1989; 8: 504–514.

    CAS  PubMed  Google Scholar 

  13. Després JP, Lemieux I, Prud’homme D . Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716–720.

    PubMed  PubMed Central  Google Scholar 

  14. Després JP . Health consequences of visceral obesity. Ann Med 2001; 33: 534–541.

    PubMed  Google Scholar 

  15. Wong S, Janssen I, Ross R . Abdominal adipose tissue distribution and metabolic risk. Sports Med 2003; 33: 709–726.

    PubMed  Google Scholar 

  16. National Cholesterol Education Program (NCEP). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

  17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735–2752.

    PubMed  Google Scholar 

  18. Kahn R, Buse J, Ferrannini E, Stern M . The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289–2304.

    PubMed  Google Scholar 

  19. Reaven G . The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33: 283–303.

    PubMed  Google Scholar 

  20. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C . Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 2004; 109: 433–438.

    PubMed  Google Scholar 

  21. Underwood PM . Cardiovascular risk, the metabolic syndrome and the hypertriglyceridaemic waist. Curr Opin Lipidol 2004; 15: 495–497.

    CAS  PubMed  Google Scholar 

  22. Bos G, Dekker JM, Heine RJ . Non-HDL cholesterol contributes to the ‘hypertriglyceridemic waist’ as a cardiovascular risk factor: the Hoorn study. Diabetes Care 2004; 27: 283–284.

    PubMed  Google Scholar 

  23. Hiura Y, Acklin F, Newman J, Steinbeck K, Caterson ID, Mahajan D et al. Hypertriglyceridemic waist as a screening tool for CVD risk in indigenous Australian women. Ethn Dis 2003; 13: 80–84.

    PubMed  Google Scholar 

  24. Solati M, Ghanbarian A, Rahmani M, Sarbazi N, Allahverdian S, Azizi F . Cardiovascular risk factors in males with hypertriglycemic waist (Tehran Lipid and Glucose Study). Int J Obes Relat Metab Disord 2004; 28: 706–709.

    CAS  PubMed  Google Scholar 

  25. St-Pierre J, Lemieux I, Vohl MC, Perron P, Tremblay G, Despreś JP et al. Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. Am J Cardiol 2002; 90: 15–18.

    CAS  PubMed  Google Scholar 

  26. Lemieux I, Alméras N, Mauriège P, Blanchet C, Dewailly E, Bergeron J et al. Prevalence of ‘hypertriglyceridemic waist’ in men who participated in the Quebec Health Survey: association with atherogenic and diabetogenic metabolic risk factors. Can J Cardiol 2002; 18: 725–732.

    PubMed  Google Scholar 

  27. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men? Circulation 2000; 102: 179–184.

    CAS  PubMed  Google Scholar 

  28. Blackburn P, Lamarche B, Couillard C, Pascot A, Bergeron N, Prud’homme D et al. Postprandial hyperlipidemia: another correlate of the ‘hypertriglyceridemic waist’ phenotype in men. Atherosclerosis 2003; 171: 327–336.

    CAS  PubMed  Google Scholar 

  29. LaMonte MJ, Ainsworth BE, DuBose KD, Grandjean PW, Davis PG, Yanowitz FG et al. The hypertriglyceridemic waist phenotype among women. Atherosclerosis 2003; 171: 123–130.

    CAS  PubMed  Google Scholar 

  30. Kahn HS, Valdez R . Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr 2003; 78: 928–934.

    CAS  PubMed  Google Scholar 

  31. Tanko LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C . Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 2005; 111: 1883–1890.

    CAS  PubMed  Google Scholar 

  32. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K . Pathophysiology and pathogenesis of visceral fat obesity. Obes Res 1995; 3 (Suppl 2): 187S–194S.

    PubMed  Google Scholar 

  33. Flier JS . The adipocyte: storage depot or node on the energy information superhighway? Cell 1995; 80: 15–18.

    CAS  PubMed  Google Scholar 

  34. Després JP . Inflammation and cardiovascular disease: is abdominal obesity the missing link? Int J Obes Relat Metab Disord 2003; 27 (Suppl 3): S22–S24.

    PubMed  Google Scholar 

  35. Juhan-Vague I, Morange P, Renucci JF, Alessi MC . Fibrinogen, obesity and insulin resistance. Blood Coagul Fibrin 1999; 10: S25–S28.

    Google Scholar 

  36. Juhan-Vague I, Alessi MC . Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70: 138–143.

    CAS  PubMed  Google Scholar 

  37. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG . Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057–2063.

    CAS  PubMed  Google Scholar 

  38. Juhan-Vague I, Alessi MC, Vague P . Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28: 371–380.

    CAS  PubMed  Google Scholar 

  39. Juhan-Vague I, Alessi MC . PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656–660.

    CAS  PubMed  Google Scholar 

  40. Juhan-Vague I, Alessi MC . Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue. Thromb Haemost 1999; 82: 832–836.

    CAS  PubMed  Google Scholar 

  41. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196–4200.

    CAS  PubMed  Google Scholar 

  42. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW . C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–978.

    CAS  PubMed  Google Scholar 

  43. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002; 87: 5662–5667.

    CAS  PubMed  Google Scholar 

  44. Côté M, Mauriège P, Bergeron J, Alméras N, Tremblay A, Lemieux I et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005; 90: 1434–1439.

    PubMed  Google Scholar 

  45. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85–89.

    CAS  PubMed  Google Scholar 

  46. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (London) 2002; 103: 137–142.

    CAS  Google Scholar 

  47. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–1599.

    CAS  PubMed  Google Scholar 

  48. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB . Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730–1737.

    CAS  PubMed  Google Scholar 

  49. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I . Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29–33.

    CAS  PubMed  Google Scholar 

  50. Chandran M, Phillips SA, Ciaraldi T, Henry RR . Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442–2450.

    CAS  PubMed  Google Scholar 

  51. Trujillo ME, Scherer PE . Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167–175.

    CAS  PubMed  Google Scholar 

  52. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239–243.

    CAS  PubMed  Google Scholar 

  53. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459–469.

    CAS  PubMed  Google Scholar 

  54. Gale EAM . The myth of the metabolic syndrome. Diabetologia 2005; 48: 1679–1683.

    PubMed  Google Scholar 

  55. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.

    PubMed  Google Scholar 

  56. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn study. Circulation 2005; 112: 666–673.

    PubMed  Google Scholar 

  57. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689.

    CAS  PubMed  Google Scholar 

  58. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–957.

    PubMed  Google Scholar 

  59. Perry IJ, Wannamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti KG . Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol 1996; 144: 224–234.

    CAS  PubMed  Google Scholar 

  60. Pyörälä K . Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131–141.

    PubMed  Google Scholar 

  61. Welborn TA, Wearne K . Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154–160.

    CAS  PubMed  Google Scholar 

  62. Lamarche B, Lemieux I, Després JP . The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999; 25: 199–211.

    CAS  PubMed  Google Scholar 

  63. Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Després JP et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001; 161: 2474–2480.

    CAS  PubMed  Google Scholar 

  64. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men. The Quebec Cardiovascular Study. Arch Intern Med 2001; 161: 2685–2692.

    CAS  PubMed  Google Scholar 

  65. Lamarche B, Tchernof A, Mauriège P, Cantin B, Dagenais GR, Lupien PJ et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955–1961.

    CAS  PubMed  Google Scholar 

  66. St-Pierre AC, Cantin B, Bergeron J, Pirro M, Dagenais GR, Després JP et al. Inflammatory markers and long-term risk of ischemic heart disease in men. A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 2005; 182: 315–321.

    CAS  PubMed  Google Scholar 

  67. Lemieux I, Lamarche B, St-Pierre A, Mauriège P, Dagenais GR, Després JP . Evidence from the Québec Cardiovascular Study that the Framingham risk chart may not detect a significant proportion of high risk men with the features of the insulin resistance syndrome. Eur Heart J 2001; 22: 630 (abstract).

    Google Scholar 

  68. Balkau B, Charles MA . Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442–443.

    CAS  PubMed  Google Scholar 

  69. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation, Part 1: diagnosis and classification of diabetes mellitus: Geneva; 1999.

  70. Alberti KG, Zimmet P, Shaw J . The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–1062.

    PubMed  Google Scholar 

  71. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y et al. American college of endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237–252.

    PubMed  Google Scholar 

  72. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350.

    CAS  PubMed  Google Scholar 

  73. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.

    CAS  PubMed  Google Scholar 

  74. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000; 133: 92–103.

    CAS  PubMed  Google Scholar 

  75. Dumont M, Mauriège P, Bergeron J, Després JP, Prud’homme D . Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. Int J Obes Relat Metab Disord 2001; 25: 1136–1143.

    CAS  PubMed  Google Scholar 

  76. Paré A, Dumont M, Lemieux I, Brochu M, Alméras N, Lemieux S et al. Is the relationship between adipose tissue and waist girth altered by weight loss in obese men? Obes Res 2001; 9: 526–534.

    PubMed  Google Scholar 

  77. Di Marzo V, Bifulco M, De Petrocellis L . The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771–784.

    CAS  PubMed  Google Scholar 

  78. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423–431.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946–1949.

    CAS  PubMed  Google Scholar 

  80. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662–3665.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161–202.

    CAS  PubMed  Google Scholar 

  82. Pagotto U, Pasquali R . Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 2005; 365: 1363–1364.

    PubMed  Google Scholar 

  83. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89–97.

    CAS  PubMed  Google Scholar 

  84. Gaoni Y, Mechoulam R . Hashish III: isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646–1647.

    CAS  Google Scholar 

  85. Di Marzo V, Matias I . Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585–589.

    CAS  PubMed  Google Scholar 

  86. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–1397.

    CAS  PubMed  Google Scholar 

  87. Després JP, Golay A, Sjöström L . Effect of rimonabant on body weight and the metabolic syndrome in overweight patients. N Engl J Med 2005; 353: 2121–2134.

    PubMed  Google Scholar 

  88. Pertwee RG . Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129–180.

    CAS  PubMed  Google Scholar 

  89. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298–1305.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844–1850.

    CAS  PubMed  Google Scholar 

  91. Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG . Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995; 19: 846–850.

    CAS  PubMed  Google Scholar 

  92. Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R . Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 2003; 284: E1065–E1071.

    CAS  PubMed  Google Scholar 

  93. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19: 1567–1569.

    CAS  PubMed  Google Scholar 

  94. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908–914.

    CAS  PubMed  Google Scholar 

  95. Libby P, Ridker PM, Maseri A . Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143.

    CAS  PubMed  Google Scholar 

  96. Després JP, Golay A, Sjöström L . One-year treatment with rimonabant increases plasma adiponectin levels beyond weight loss: The RIO-Lipids trial. Diabetes 2005 (abstract).

  97. Després JP . Our passive lifestyle, our toxic diet, and the atherogenic/diabetogenic metabolic syndrome: can we afford to be sedentary and unfit? Circulation 2005; 112: 453–455.

    PubMed  Google Scholar 

  98. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822–825.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Research conducted by Dr Després reviewed in the present paper has been supported by the Canadian Institutes of Health Research (CIHR) and by the Canadian Diabetes Association (CDA). The authors’ research on rimonabant has been funded by sanofi-aventis.

Author information

Authors and Affiliations

  1. Québec Heart Institute, Hôpital Laval Research Center, Québec, Québec, Canada

    J-P Després & I Lemieux

  2. Department of Social and Preventive Medicine, Université Laval, Québec, QC, Canada

    J-P Després

  3. Hôpital Laval Research Center, Québec, QC, Canada

    N Alméras

Authors
  1. J-P Després
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Lemieux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Alméras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J-P Després.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Després, JP., Lemieux, I. & Alméras, N. Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes 30 (Suppl 1), S44–S52 (2006). https://doi.org/10.1038/sj.ijo.0803278

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803278

Keywords

This article is cited by

Search

Advanced search

Quick links